Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer
Uchida, T.; Horiguchi, S.; Tanaka, Y.; Yamamoto, H.; Kunii, N.; Motohashi, S.; Taniguchi, M.; Nakayama, T.; Okamoto, Y.
Cancer Immunology and ImmunoTherapy 57(3): 337-345
2008
ISSN/ISBN: 0340-7004
Accession: 077180668
PDF emailed within 1 workday: $29.90
Related References
Uchida, T.; Horiguchi, S.; Tanaka, Y.; Yamamoto, H.; Kunii, N.; Motohashi, S.; Taniguchi, M.; Nakayama, T.; Okamoto, Y. 2008: Phase i study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer Cancer Immunology Immunotherapy: Cii 57(3): 337-345Kurosaki, M.; Horiguchi, S.; Yamasaki, K.; Uchida, Y.; Motohashi, S.; Nakayama, T.; Sugimoto, A.; Okamoto, Y. 2011: Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer Cancer Immunology Immunotherapy: Cii 60(2): 207-215
Kunii, N.; Horiguchi, S.; Motohashi, S.; Yamamoto, H.; Ueno, N.; Yamamoto, S.; Sakurai, D.; Taniguchi, M.; Nakayama, T.; Okamoto, Y. 2009: Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma Cancer Science 100(6): 1092-1098
Toyoda, T.; Kamata, T.; Tanaka, K.; Ihara, F.; Takami, M.; Suzuki, H.; Nakajima, T.; Ikeuchi, T.; Kawasaki, Y.; Hanaoka, H.; Nakayama, T.; Yoshino, I.; Motohashi, S. 2020: Phase Ii study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer Journal for ImmunoTherapy of Cancer 8(1)
Ishibashi, F.; Sakairi, Y.; Iwata, T.; Moriya, Y.; Mizobuchi, T.; Hoshino, H.; Yoshida, S.; Hanaoka, H.; Yoshino, I.; Motohashi, S. 2020: A phase i study of loco-regional immunotherapy by transbronchial injection of α-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer Clinical Immunology 215: 108457
Spencer, S.; Wheeler, R.; Peters, G.; Meredith, R.; Beenken, S.; Nabel, L.; Wooten, A.; Soong, S.-J.; Salter, M. 2003: Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer Head and Neck 25(2): 118-122
Swiecicki, P.L.; Zhao, L.; Belile, E.; Sacco, A.G.; Chepeha, D.B.; Dobrosotskaya, I.; Spector, M.; Shuman, A.; Malloy, K.; Moyer, J.; McKean, E.; McLean, S.; Wolf, G.T.; Eisbruch, A.; Prince, M.; Bradford, C.; Carey, T.; Worden, F.P. 2015: A phase Ii study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer Investigational new Drugs 33(6): 1248-1256
Ishikawa, A.; Motohashi, S.; Ishikawa, E.; Fuchida, H.; Higashino, K.; Otsuji, M.; Iizasa, T.; Nakayama, T.; Taniguchi, M.; Fujisawa, T. 2005: A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer Clinical Cancer Research 11(5): 1910-1917
Ishikawa, A.; Motohashi, S.; Ishikawa, E.; Fuchida, H.; Higashino, K.; Otsuji, M.; Iizasa, T.; Nakayama, T.; Taniguchi, M.; Fujisawa, T. 2005: A phase i study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 11(5): 1910-1917
Motohashi, S.; Nagato, K.; Kunii, N.; Yamamoto, H.; Yamasaki, K.; Okita, K.; Hanaoka, H.; Shimizu, N.; Suzuki, M.; Yoshino, I.; Taniguchi, M.; Fujisawa, T.; Nakayama, T. 2009: A phase I-Ii study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer Journal of Immunology 182(4): 2492-2501
Nagato, K.; Motohashi, S.; Ishibashi, F.; Okita, K.; Yamasaki, K.; Moriya, Y.; Hoshino, H.; Yoshida, S.; Hanaoka, H.; Fujii, S.-I.; Taniguchi, M.; Yoshino, I.; Nakayama, T. 2012: Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells Journal of Clinical Immunology 32(5): 1071-1081
Strnad, V.; Lotter, M.; Kreppner, S.; Fietkau, R. 2014: Re-irradiation with interstitial pulsed-dose-rate brachytherapy for unresectable recurrent head and neck carcinoma BrachyTherapy 13(2): 187-195
Van Schalkwyk, M.C.I.; Papa, S.E.; Jeannon, J.-P.; Guerrero Urbano, T.; Spicer, J.F.; Maher, J. 2013: Design of a phase i clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer Human Gene Therapy. Clinical Development 24(3): 134-142
Cacicedo, J.; Bilbao, P. 2014: Stereotactic body radiotherapy: an attractive treatment modality for recurrent head and neck carcinoma. (Regarding Lartigau et al.: Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer) RadioTherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 111(3): 482-483
Okamoto, Y.; Fujikawa, A.; Kurosaki, M.; Yamasaki, K.; Sakurai, D.; Horiguchi, S.; Nakayama, T. 2011: Nasal submucosal administration of antigen-presenting cells induces effective immunological responses in cancer immunotherapy Advances in Oto-Rhino-Laryngology 72: 149-152